Roivant Sciences Ltd. (ROIV)

Market Cap	14.51B
Revenue (ttm)	20.33M
Net Income (ttm)	-373.97M
Shares Out	695.49M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,676,372
Open	20.36
Previous Close	20.30
Day's Range	20.30 - 20.90
52-Week Range	8.73 - 21.35
Beta	1.23
Analysts	Strong Buy
Price Target	21.19 (+1.58%)
Earnings Date	Nov 10, 2025

About ROIV

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 750
• Stock Exchange: NASDAQ
• Ticker Symbol: ROIV
• Website: https://roivant.com

Analyst Summary

According to 8 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $21.19, which is an increase of 1.58% from the latest price.

Price Target

$21.19

(1.58% upside)

Analyst Consensus: Strong Buy